AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the United States. Revenue climbed 12 percent to ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Profit and revenue for British-Swedish drug major AstraZeneca were up in the second quarter, the company reported on Tuesday, ...

This was the ADR's second consecutive day of losses.

The company plans to invest billions in a new drug manufacturing hub in Virginia, dedicated to chronic disease treatments, ...

The company hopes to move on from scandals in China, after indicating that any impact from probes in its second-biggest ...

AstraZeneca PLC closed 18.54% short of its 52-week high of £133.88, which the company reached on September 3rd.

07-03-2025 DESIGN Bentley modernized its logo without pulling ‘a Jaguar’ The British luxury automaker redesigned its emblem for just the fifth time in over a century.

(Reuters) -AstraZeneca’s experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...